CA-DOCUSIGN
DocuSign, Inc. (DocuSign®) announced the DocuSign Summer ‘14 Release of the company’s industry-leading Digital Transaction Management (DTM) platform, available 6 June 2014. DocuSign’s latest release includes new DTM features for automating manual, paper-based processes to help organisations transform into fully digital businesses.
Enhancements include:
- Every employee in an organisation can effortlessly complete transactions digitally via deeper integrations with Microsoft Office and SharePoint
- Organisations conducting business in the European Union (EU) will be able to sign directly within DocuSign’s DTM platform using EU-accredited OpenTrust digital signatures
- Real estate agents and brokers can better manage and accelerate complex transactions using DocuSign Transaction Rooms™ with industry-specific capabilities like customisable document checklists, user roles and permissions
- Organisations and developers can integrate the DocuSign DTM platform into existing mobile apps with the world’s first eSignature Mobile SDK, providing a high-quality, fully-native signing and sending experience to customers
“The DocuSign Summer ‘14 Release adds rich features and functionality that will help customers of every size, industry and geography keep business digital for dramatic ROI, increased security and compliance, and better customer experiences,” said Matt Malden, chief product officer, DocuSign. “We’re bringing the value of DocuSign DTM to customers around the globe through our deeper integrations with Microsoft Office and OpenTrust.”
Deeper Office and SharePoint Integrations Bring DTM Benefits to Microsoft Users Worldwide
The DocuSign Summer ‘14 Release features new versions of DocuSign Apps for Microsoft, enabling access to The Global Standard for Digital Transaction Management™ directly within Office 365, including Office 2013 and SharePoint. DocuSign for Outlook v2.0 updates provide Outlook 2013 and Outlook Web App users additional multi-party signer scenarios, including the ability to add a signer to an in-process workflow directly from Outlook and automatically save a signed document to OneDrive for Business. DocuSign for Word v2.0 now allows Word 2013 users the ability to connect to DocuSign using a personal Microsoft ID in addition to a Office 365 account, and offers a more guided experience making it easier than ever to go from editing a document to DocuSigning in seconds. DocuSign for SharePoint Online v1.2 includes several new enhancements for DocuSign transaction management capabilities.
DocuSign with OpenTrust Digital Signatures Delivers EU Compliant Digital Signatures
Customers will be able to send documents to be DocuSigned from within DocuSign Business, Enterprise and Platform editions using a cloud-based, X.509 digital signature from OpenTrust, the leading European provider of digital signatures. DocuSign’s DTM platform combined with OpenTrust’s ETSI-compliant (European Technology Standards Institute), independently EU-accredited digital signature helps global and European customers increase assurance for higher-value and/or risk transactions.
DocuSign Transaction Rooms Help Real Estate Professionals Accelerate Multi-Party/Document Deals
Expanded functionality of DocuSign Transaction Rooms on the DocuSign DTM platform provides a simple, mobile, flexible and secure end-to-end experience in the cloud for brokers and agents who need to complete complex transactions with multiple documents and parties. Now part of DocuSign’s Real Estate Plus and Real Estate Plus Broker editions, DocuSign Transaction Rooms feature customizable document checklists, user roles and permissions to assure compliance and reduce costly errors. Brokers can provision accounts, invite users, and manage preferences quickly, easily and securely. The most commonly used real estate forms are available at broker and agent fingertips with DocuSign’s full integration with ZipForm, the industry leader in real estate forms software. Documents can be quickly and securely DocuSigned from iOS and Android tablets to close deals quickly on the spot.
“When you’re making a technology investment, it’s important to choose solutions that not only add value to an agent’s life, but also benefit the enterprise,” says Scott Crowley, SVP and CIO of Berkshire Hathaway Home Services, Fox & Roach | The Trident Group. “DocuSign’s Broker Edition is the Digital Transaction Management platform we’ve been looking for to bring together core business units and manage transactions from beginning to end. It’s the industry-leading solution that combines the best technology in digital forms, eSignature, and document collaboration into one powerful, reliable, and easy-to-use platform.”
“At MRED, we are always researching new products and services to better serve the real estate brokerage community," says Russ Bergeron, president and CEO, Midwest Real Estate Data, the Chicagoland multiple listing service (MLS). “The demand to digitise the real estate transaction has been skyrocketing—from our top-producing brokers as well as their clients. We took advantage of DocuSign’s partnership with the National Association of REALTORS® and fully integrated DocuSign’s platform within our MLS system. In the first year our customers DocuSigned more than 42,000 transactions. Our team and our customers absolutely love being able to DocuSign anytime, anywhere, on any device.”
DocuSign Mobile SDK Beta Programme
The DocuSign Summer ‘14 Release includes the opening of a three-month Beta Programme for iOS application developers looking to implement high-quality, native mobile sending and signing experiences to keep business digital. Select programme participants will be able to take advantage of dedicated developer support and future promotional opportunities. Recently cited by ProgrammableWeb as “The Clear Leader,” DocuSign is further simplifying the process of building secure, authenticated DTM capabilities directly into native apps using the DocuSign Mobile SDK. More details and registration are available at www.docusign.com/mobilesdk .
For more information on the DocuSign Summer ‘14 Release, visit www.docusign.com/docusign-summer-14-release .
About DocuSign Inc.
DocuSign ® is The Global Standard for Digital Transaction Management™. Global enterprises, business departments, individual professionals, and consumers have standardised on DocuSign, with more than 40,000 new users joining the DocuSign Global Network every day. Today, that network includes millions of users in 188 countries. DocuSign's DTM platform supports legally compliant electronic and digital signature processes tailored to meet requirements globally with localisation in 43 languages. Companies and individuals DocuSign to accelerate transaction times to increase speed to results, reduce costs, increase security and compliance, and delight customers across nearly every industry – from financial services, insurance, technology, healthcare, manufacturing, communications, real estate, retail, and consumer goods to higher education, non-profit and others – as well as every business department, including sales, finance, operations, procurement, HR/staffing, legal, and customer support. For more information, visit www.docusign.co.uk . Visit the DocuSign blog at www.docusign.co.uk/blog and follow DocuSign on Twitter , LinkedIn , and Facebook .
DocuSign is a registered trademark of DocuSign, Inc. All other trademarked names or terms used in this document are the properties of their respective owners.
Contact:
Chameleon PR for DocuSign EMEA PR
Julie Walsh, +44 207 680 5500
docusign@chameleonpr.com
or
DocuSign,
Inc.
Gregor Perotto, +1 206-576-8081
gregor.perotto@docusign.com
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum